Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports no results yet and only indicates an ongoing randomized placebo-controlled trial investigating the effects of microneedling combined with topical dutasteride solution for treating androgenetic alopecia.

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

This study found that dutasteride-loaded nanostructured lipid carriers coated with a stearic acid-chitosan oligomer are stable, less cytotoxic, and suitable for topical delivery to promote hair growth.

This study found that dutasteride pretreatment reduced certain sedative effects of alcohol and may decrease drinking behavior in adult men, likely by impacting neuroactive steroid levels.

This study found that coadministration of 5α-reductase inhibitors with oral testosterone in oil significantly increases serum testosterone levels in medically castrated men compared to testosterone alone, with food intake minimally affecting these levels.

This study found that dutasteride completely suppressed the formation of 5alpha-dihydro metabolites in cultured human skin cells, suggesting its potential use in acne and androgenetic alopecia.

This study found that the pharmacological inhibition of 5-α reductases with finasteride and dutasteride can reduce neurosteroid synthesis in glioblastoma-derived cell lines, potentially impacting GBM survival.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

This study found that a 400-mg dose of oral testosterone with dutasteride increases serum testosterone levels for 8–10 hours in hypogonadal men, with the nanomilled formulation unaffected by food, suggesting a practical twice-daily therapy option.

This study optimized the reaction conditions for the stereoselective hydrogenation of a compound used in manufacturing finasteride and dutasteride, improving the selectivity for the desired isomer.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.

Dutasteride and minoxidil mesotherapy effectively treats hair loss with minimal side effects.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This study found that oral minoxidil was associated with short-term improvements in clinical severity for androgenetic alopecia, whereas oral dutasteride did not show significant early clinical changes in the six-month follow-up.

This study reports that dutasteride, used alone or with tamsulosin, effectively reduces acute urine retention and surgery risk in men with benign prostatic hyperplasia, and may lower prostate cancer incidence, suggesting potential chemopreventive benefits.

This study demonstrates that massage significantly enhances the follicular targeting of dutasteride-loaded nanocapsules, increasing drug accumulation in hair follicles by up to 5 times.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This study found that finasteride- and dutasteride-loaded iron oxide nanoparticles improved drug penetration in the skin, suggesting they may be promising for topical alopecia therapies.

This study explored using a chitosan oligomer coating for topical delivery of dutasteride-loaded nanostructured lipid carriers, aiming to reduce systemic exposure and cytotoxicity.

This study found that a dutasteride tablet formulation using cyclodextrin complex, solubilizing polymer, and surfactant achieved similar bioavailability in beagle dogs to that of a commercial capsule.

This study concluded that mesotherapy with a dutasteride-containing solution was the most effective option for treating androgenetic alopecia in males, promoting hair growth and reducing hair loss.

In this randomized study, intradermal injections of dutasteride effectively improved androgenetic alopecia in 15 male patients, showing significant clinical improvement within one month and being well-tolerated without notable side effects, though the improvement was negatively correlated with longer disease duration.

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

This study found that dutasteride effectively improved urinary symptoms, reduced acute urinary retention risk, and decreased prostate volume in men with moderate to severe BPH over two years.

This study found that SRD5a-3 is a highly efficient enzyme for converting hormones into androgens, with dutasteride being a much more potent inhibitor of SRD5a-3 than SRD5a-2.

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

This study suggests that dutasteride may be a viable alternative for Korean men with androgenetic alopecia who do not respond to finasteride, as it improved hair density and thickness in most participants.